Known targets — ChEMBL curated mechanism
ACVR1ADORA1ADORA2AADORA2BADORA3ESR1ESR2FLT3GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSC1GSK3AGSK3BHRH1HRH2HTR7IDH1IDH2IMPA1IRAK1JAK1JAK2JAK3MEN1OPRM1P2RX3PDE5ASCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASIGMAR1SLC6A2SYKTACR1TOP2ATYK2
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 1/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HMGCR | P04035 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | ACLY | P53396 | 3/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | CPT2 | P23786 | 1/20 | 0.31 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citric Acid SCHEMBL104389 | 0.98 | CA4 (0.70) | CA4ALDH1A1HMGCRCHRM1TBXA2R | |
| Citric Acid SCHEMBL11132767 | 0.98 | CA4 (0.70) | CA4ALDH1A1HMGCRCHRM1TBXA2R | |
| Citric Acid SCHEMBL1303278 | 0.98 | CA4 (0.77) | CA4ALDH1A1HMGCRCHRM1TBXA2R | |
| Citric Acid SCHEMBL4889866 | 0.98 | CA4 (0.70) | CA4ALDH1A1HMGCRCHRM1TBXA2R | |
| Citric Acid SCHEMBL5471630 | 0.98 | CA4 (0.76) | CA4ALDH1A1HMGCRCHRM1TBXA2R | |
| Citric Acid SCHEMBL11157533 | 0.96 | CA4 (0.74) | CA4ALDH1A1HMGCRCHRM1TBXA2R | |
| Citric Acid SCHEMBL1410612 | 0.96 | CA4 (0.67) | CA4ALDH1A1HMGCRCHRM1TBXA2R | |
| Citric Acid SCHEMBL22124529 | 0.96 | CA4 (0.74) | CA4ALDH1A1HMGCRCHRM1TBXA2R | |
| Citric Acid SCHEMBL27950162 | 0.96 | CA4 (0.74) | CA4ALDH1A1HMGCRCHRM1TBXA2R | |
| Citric Acid SCHEMBL10417838 | 0.96 | CA4 (0.74) | CA4ALDH1A1HMGCRCHRM1TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1798 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122080107-A | Method for green extraction of glycyrrhizic acid | — | 2026-05-26 | — | — | CN | claimed |
| CN-122017257-A | Detection method and detection kit for oxidized low-density lipoprotein | 济南玖方生物科技有限公司 | 2026-05-12 | — | — | CN | claimed |
| US-20260108477-A1 | CYCLOBENZAPRINE TREATMENT FOR FIBROMYALGIA | TONIX PHARMA LTD (IE) | 2026-04-23 | — | — | US | claimed |
| US-20260060973-A1 | Ophthalmic Composition for Treating Non-Infectious Inflammatory Diseases | VIVAVISION BIOTECH LTD (CN) | 2026-03-05 | — | — | US | claimed |
| EP-4702973-A1 | OPHTHALMIC COMPOSITION FOR TREATING NON-INFECTIOUS INFLAMMATORY DISEASES | Vivavision Biotech Ltd. (CN) | 2026-03-04 | — | — | EP | claimed |
| EP-4702974-A1 | OPHTHALMIC COMPOSITION CONTAINING VVN001 | Vivavision Biotech Ltd. (CN) | 2026-03-04 | — | — | EP | claimed |
| US-20260014404-A1 | LONG-TERM FIRE RETARDANT WITH CORROSION INHIBITORS AND METHODS FOR MAKING AND USING SAME | PERIMETER SOLUTIONS, LP (US) | 2026-01-15 | — | — | US | claimed |
| WO-2025264733-A1 | LONG-TERM FIRE RETARDANT WITH CORROSION INHIBITORS AND METHODS FOR MAKING AND USING SAME | PERIMETER SOLUTIONS, LP (US) | 2025-12-26 | — | — | WO | claimed |
| US-20250322926-A1 | EARLY ONSET RESPONSE, FAVORABLE TOLERABILITY, AND SIDE EFFECT PROFILE IN THE TREATMENT OF FIBROMYALGIA | TONIX Pharmaceuticals Holding Corp (US) | 2025-10-16 | — | — | US | claimed |
| US-20250313678-A1 | FOAMABLE POLYOLEFIN COMPOSITION PROVIDING INCREASED FLEXIBILITY | BOREALIS AG (AT) | 2025-10-09 | — | — | US | claimed |
| EP-0726717-A1 | CLEANING METHODS AND COMPOSITIONS FOR FOOD- AND FEEDSTUFF | THE PROCTER & GAMBLE COMPANY (US) | 1996-08-21 | — | — | EP | claimed |
| WO-1995012326-A1 | CLEANING METHODS AND COMPOSITIONS FOR FOOD- AND FEEDSTUFF | THE PROCTER & GAMBLE COMPANY (US) | 1995-05-11 | — | — | WO | claimed |
| EP-0474040-B1 | Efferescent powder component and process for its production | BAYER AG (DE) | 1994-04-06 | — | — | EP | claimed |
| EP-0188313-B1 | ORAL HYGIENE COMPOSITIONS | BEECHAM GROUP PLC (GB) | 1993-07-14 | — | — | EP | claimed |
| CN-1066560-A | Instant disinfectant tablet and preparation method | GAO JIANSHENG (CN) | 1992-12-02 | — | — | CN | claimed |
| US-5021324-A | Aqueous solution of dipotassium hydroxyethylidenediphosphonate | POLYCHROME CORPORATION (US) | 1991-06-04 | — | — | US | claimed |
| US-4961927-A | Clear solution containing lysozyme hydrochloride and dipotassium glycyrrhizinate | EISAI CO., LTD. (JP) | 1990-10-09 | — | — | US | claimed |
| US-4824664-A | ANTIHISTAMINES | LABORATOIRES SMITH KLINE & FRENCH (FR) | 1989-04-25 | — | — | US | claimed |
| US-4819675-A | Chemical removal of dental plaque | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 1989-04-11 | — | — | US | claimed |
| US-4200586-A | Inhibiting the carbon-carbon double bond isomerization of substituted or unsubstituted hydrocarbon compounds | PHILLIPS PETROLEUM COMPANY (US) | 1980-04-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260108477-A1 | CYCLOBENZAPRINE TREATMENT FOR FIBROMYALGIA | FAAH, CRH, FUCA2 | CA4 398/4885ALDH1A1 812/4885HMGCR 2082/4885 |
| US-20260014404-A1 | LONG-TERM FIRE RETARDANT WITH CORROSION INHIBITORS AND METHODS FOR MAKING AND USING SAME | SLC6A12, SLC11A2, KCNN1 | CA4 443/4885ALDH1A1 4616/4885HMGCR 3638/4885 |
| US-20260060973-A1 | Ophthalmic Composition for Treating Non-Infectious Inflammatory Diseases | JAK1, TYK2, JAK3 | CA4 3086/4885ALDH1A1 2996/4885HMGCR 4689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.